Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Recruiting now · Not applicable

Conditions studied: Cardiogenic Shock, Heart Failure, Ambulatory Hemodynamic Monitoring

In brief

Pilot Prospective Randomized Unblinded Pragmatic Trial of Pulmonary Artery Hemodynamic Monitoring Following Hospitalization for Cardiogenic Shock

Key facts

Study ID

NCT04419480

Run by

Inova Health Care Services

People needed

40

Starts

2020-12-31

Expected to finish

2028-12-31

Last updated by the study team

2026-03-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject or legal representative has signed Informed Consent Form (ICF) and the patient has the capacity to participate in the study and complete the study questionnaires, in the estimation of the study investigator.
• Age ≥ 18 years
• NYHA Class III with dyspnea upon mild physical activity, regardless of left ventricular ejection fraction (LVEF).
• Survive to discharge during a current hospital admission with cardiogenic shock (CS) as defined by clinical criteria previously used in cardiogenic shock trials: systolic blood pressure < 90 mmHg for > 30 minutes or requiring infusion of catecholamines to maintain the systolic blood pressure above 90 mmHg, with evidence of end-organ dysfunction such as pulmonary edema or impaired end-organ perfusion including altered mentation, oliguria with urine output < 30 mL/h, or serum lactate > 2 mmol/L (5). Hemodynamic criteria include cardiac index ≤ 1.8 L/min/m2 without vasoactive pharmacologic agents, or cardiac index ≤ 2.2 L/min/m2 and pulmonary artery occlusion pressure ≥ 15 mmHg with vasoactive agents.
• Patients must have internet and phone access (to allow communication of the implanted device with the researchers).

You may not qualify if…

• Technical obstacles which pose an inordinately high procedural risk, in the judgment of the investigator.
• Treatment with ongoing mechanical circulatory support (MCS) such as a durable left ventricular assist device (LVAD) or recipient of a heart transplantation for the treatment of cardiogenic shock during the index hospitalization for CS.
• If of childbearing potential with a positive pregnancy test.
• Transition to hospice care.
• Intolerance to or inability to adhere to antiplatelet therapy for 1 year after device implantation.
• Presence of an active, uncontrolled infection.
• Any condition other than heart failure that could limit survival to less than 6 months
• Discharge to facility other than acute rehabilitation or to the ambulatory setting.
• No access to internet or phone.

Where it is running

• Inova Fairfax Medical Campus — Falls Church, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.